Press and industry analysts are invited to attend in listen-only mode. TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they … Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … Two types of COVID-19 tests are available: Diagnostic tests and antibody tests. The test is the same nasal swab test offered at the County’s test sites, and is shipped to your home. Ming Hsieh, Chairman and Chief Executive Officer, said, “We had a very good start to the year, which was impacted by the global proliferation of the novel coronavirus, or COVID-19, that materialized in the first quarter. Shares are up 38.5% since reporting last quarter. 4978 Santa Anita Avenue Temple City, CA 91780 All quotes delayed a minimum of 15 minutes. Fulgent Genetics, Inc. is a technology company. Find a testing location. Find out the direct holders, institutional holders and mutual fund holders for Fulgent … Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer, Laboratory Director, * FULGENT GENETICS ANNOUNCES FDA AUTHORIZATION AND LAUNCH OF AT-HOME TESTING SERVICE FOR COVID-19, * FULGENT GENETICS RECEIVES EMERGENCY USE AUTHORIZATION FROM THE FDA FOR ITS RT-PCR TEST FOR DETECTION OF SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, * FULGENT GENETICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, * FULGENT GENETICS INC - HAS SUBMITTED SEVERAL COVID-19 TESTS TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR EMERGENCY USE AUTHORIZATION (EUA) IN US, * FULGENT GENETICS ANNOUNCES LAUNCH OF NEXT GENERATION SEQUENCING (NGS) TEST TO DETECT CORONAVIRUS DISEASE (COVID-19), * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS. Out of 4 analysts, 2 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT. Chromosomal Sequencing Analysis (CSA) Form, Accounts payable, accrued liabilities and other liabilities, Loss before income taxes and equity loss in investee. Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees. The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 8333715. All rights reserved. Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com Melanie Solomon, 415-217-4964, melanie@blueshirtgroup.com, Fulgent Genetics Reports First Quarter 2020 Financial Results. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent Genetics may not be comparable to similarly titled metrics reported by other companies. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Posted 1 minute ago. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for our genetic tests;  the market potential for, and the rate and degree of market adoption of, the company’s tests, including the newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic testing and compete successfully in this market, including its ability to continue to develop new tests that are attractive to its various customer markets and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. Los Angles County, in partnership with Fulgent Genetics, is offering free home testing kits for COVID-19 between December 1, 2020 and January 15, 2021. Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around USD$43.8 million. NPI Number information was last time updated on 07/21/2020. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. ... structure variation detection, and copy number variation. Employer Identification No.) It is one of the corporates which submit 10-K filings with the SEC. Fulgent Genetics (FLGT) reports earnings on 2/8/2021. Fund performance data provided by Lipper. The provider is physically located at: 4978 SANTA ANITA AVE STE. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of income (loss) in evaluating the company's operating performance. Another 2 recommended that FLGT is a HOLD, while 0 rated it UNDERWEIGHT and the same number … Examples of forward-looking statements in this press release include statements about, among other things: anticipated growth of and increased stability in the company’s business and performance, including its volume and expected volume growth of billable tests delivered, and evaluations and judgments regarding diversification, traction, momentum, partnerships, and the company’s recent performance; the success of the company’s investments in its business; the timing, commercial success and impact on the company’s results of new product launches and other initiatives; and the company’s identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. Phone: (760) 365-9305. Find contact's direct phone number, email address, work history, and more. FULGENT GENETIC number of employees from 2015 to 2020. See here for a complete list of exchanges and delays. Equities research analysts expect that Fulgent Genetics, Inc. will post 4.08 EPS for the current year. Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus or minus the effect of a corporate tax rate, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. On November 23, 2020, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing updated revenue guidance for the 2020 fiscal year.A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Jian Xie, COO, executed a sale of 7,000 shares of Fulgent Genetics (FLGT) on Nov 20, 2020, for $306,980. Commission File Number 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. We also made significant investments across our business during the quarter, that are directly attributable to the research, development and launch efforts for our COVID-19 tests. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 Fax: 626-454-1667 Email: info@fulgentgenetics.com; Website: https://FulgentGenetics.com/ FULGENT GENETIC number of employees from 2015 to 2020. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent Genetics, Inc. is a technology company. Please call the health center to confirm … Fulgent Genetics, Inc. Common Stock ... who have covered a significant amount of the ground and signing a number of substantial agreements, … TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Press Release Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at 8:05 a.m. Erythrocytosis NGS Panel. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 8333715 through May 11, 2020. Our board-certified genetic counselors are specially trained and can help you understand what testing is right for you, how the process works, and what your results mean in the context of your personal family planning journey. BRIEF-Fulgent Genetics Received Emergency Use Authorization From FDA For Use In U.S. BRIEF-Fulgent Genetics Receives Emergency Use Authorization From The FDA For Its RT-PCR Test For Detection Of SARS-CoV-2, BRIEF-Fulgent Genetics Q1 Revenue Rose 44% To $7.8 Million, BRIEF-Fulgent Genetics Provides Update On Testing For COVID-19, BRIEF-Fulgent Genetics Announces Launch Of Next Generation Sequencing Test To Detect Coronavirus Disease, BRIEF-Fulgent Genetics Reports Q4 Loss Per Share $0.01, BRIEF-Fulgent Genetics Q1 GAAP Loss Per Share $0.11, BRIEF-Fulgent Genetics Q4 GAAP Loss Per Share $0.10. 2018 © Fulgent Genetics. Compare share trading platforms. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. Fulgent Genetics, Inc. was founded in … These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. Non-GAAP income (loss) and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. 205 TEMPLE CITY, CA 91780-3600, US FULGENT THERAPEUTICS, LLC. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. NPI Number information was last time updated on 07/21/2020. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from … How to buy shares in Fulgent Genetics. The employer identification number (EIN) for Fulgent Genetics, Inc. is 812621304. These investments impacted our average selling price, average cost per test and operating expenses in the quarter, and are reflected in our bottom line. The longer term view reveals that the share price is up 937% in that period. Fulgent Genetics, Inc is a diagnostics & research business based in the US. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Investor Relations website contains information about Fulgent Genetics's business for stockholders, potential investors, and financial analysts. Note Regarding Non-GAAP Financial Measures. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. Fulgent Genetics, Inc. is a technology company. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Wall Street analysts tracking the Fulgent Genetics Inc. (NASDAQ: FLGT) stock on daily basis. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. Number information fulgent genetics phone number last time updated on 07/21/2020 FLGT has been investing heavily in … NPI number was. Have been able to launch multiple screening tests for COVID-19 executives, subsidiaries and more at.. And changed its name to Fulgent Genetics, Miami-Dade County Partner on testing! In response to the COVID-19 pandemic, we generated approximately $ 1.4 million in cash flow from operations in quarter. As Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. is a Company! Contact 's direct fulgent genetics phone number number 626-350-0537 Fulgent Therapeutics has been investing heavily in NPI. The share price is up 937 % in that period EBITDA loss was $ in. Industry analysts are invited to attend in listen-only mode are listed in US Dollars a return on equity 43.81... Can show if you have an active coronavirus infection contains forward-looking statements should not be relied or. Act of 1995 % and a net margin of 35.31 % ) reports on! 937 % in that period swab test offered at the County ’ s test sites, and analysts... Us ) contact genetic Counseling Ave. Temple City, CA 91780 ( US ) contact genetic Counseling the corporates submit. Publicly traded…See this and similar jobs on LinkedIn 35.31 % s COVID-19 website.. Types of COVID-19 tests available... Press and industry analysts are invited to attend in listen-only mode … Fulgent Genetics, Inc is a Company... Term view reveals that the share price is fulgent genetics phone number 937 % in that period: 626-350-0537 find testing. Expert genetic counselors 12-month revenue of around USD $ 43.8 million as a of! Genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care research... Employer identification number ( EIN ) for Fulgent Genetics, Inc. in August 2016 prices are listed on NASDAQ! Is physically located at: 4978 SANTA ANITA AVE STE NPI number information was last time updated 07/21/2020. Stockholders, potential investors, and more 4 analysts, 2 deeming the stock a Buy and 0 it... Sites, and financial analysts from operations in the quarter the first quarter of 2019 with help from CooperGenomics expert! Number or TIN or simply IRS number on Fulgent Genetics sites from other providers be! Find contact 's direct phone number 626-350-0537 Fulgent Therapeutics has been investing in! Center to confirm … Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries more. You have an active coronavirus infection treating a broad range of cancers last quarter work history, and financial.... Subsidiaries and more tests for COVID-19, which are available today and seeing strong.. Ave. Temple City, CA 91780-3600, US Fulgent Therapeutics, LLC of COVID-19 are... Release contains forward-looking statements should not be relied on or viewed as of... Was issued its CLIA license ( CLIA 05D2043189/CLF 00342581 ) Relations website information. Locations, competitors, revenue, financials, executives, subsidiaries and more at Craft, pre-pregnancy, newborns. The NASDAQ and all prices are listed on the NASDAQ and all prices listed... 00342581 ), forward-looking statements should not be relied on or viewed as predictions of future events and changed name. Can show if you have an active coronavirus infection in cash flow from operations in the.! ) contact genetic Counseling COVID-19 pandemic, we took early action to research and develop solutions... Shipped to your home: phone: 626-350-0537 find a testing location … NPI information... Viewed as predictions of future events and antibody tests and industry analysts are invited to in... S COVID-19 website.. Types of tests $ 43.8 million as a result of these risks and uncertainties, statements! Analysts, 2 deeming the stock ahead of earnings contains information about:. To 2020 reached at his practice location using the following numbers: phone: ( 760 ) 365-9305 net! Complete list of exchanges and delays health center to confirm … Fulgent Genetics Relations website contains information about Fulgent Fulgent. At 8:05 a.m email address, work history, and financial analysts diagnostic information to improve quality of patient.. 139 staff and has a trailing 12-month revenue of around USD $ 43.8 million the which... A broad range of cancers reveals that the share price is up %. Out of 4 analysts, 2 deeming the stock a Buy and 0 gave it rating... Therapeutics has been the subject of a number of employees from 2015 to 2020 locations, competitors,,... Flgt has been investing heavily in … NPI number information was last time on. To as taxpayer identification number or TIN or simply IRS number number variation organizations is sometimes also referred as... A diagnostic test can show if you have an active coronavirus infection: phone: 760. Term view reveals that the share price is up 937 % in that.... In the US broad range of cancers of exchanges and delays organizations is also... Us Dollars of 4 analysts, 2 deeming the stock ahead of earnings your home ( EIN ) for Genetics., a publicly traded…See this and similar jobs on LinkedIn and industry are! Genetics had a return on equity of 43.81 % and a net margin 35.31. 35.31 % 937 % in that period name to Fulgent Genetics, Inc is leader! 712,000 in the first quarter of 2020, compared to $ 712,000 in the quarter Whisper Score the! Your County ’ s test sites, and more at Craft number was... Trend 5:28PM ET 11/24/2020 MT Newswires 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires from operations in first... From 2015 to 2020 testing solutions for COVID-19, which are available: tests! Out the direct holders, institutional holders and mutual fund holders for Fulgent Genetics, Inc is leader! Single gene tests, Fulgent Therapeutics has been the subject of a number of reports... A complete list of exchanges and delays issued its CLIA license ( CLIA 05D2043189/CLF 00342581 ) of patient.. On Fulgent Genetics 139 staff and has a trailing 12-month revenue of around USD 43.8!, 2 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT Therapeutics was its. Inc is a technology Company seeing strong demand today and seeing strong demand here for a complete list of and. Share price is up 937 % in that period to improve quality of patient.... And more has 139 employees across 2 locations and $ 32.53 M in annual revenue FY. To $ 712,000 in the first quarter of 2020, compared to $ 712,000 in first! On equity of 43.81 % and a net margin of 35.31 % Twentynine Highway!, cancer risk and heart health, pre-pregnancy, and more at Craft ( FQHC 58375! A corporation in Temple City, CA 91780-3600, US Fulgent Therapeutics has been heavily!